This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (19)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Review  • Hypertension  • Alert me on articles by topic

Robert Toto, MD

Arch Intern Med. 2001;161:1492-1499.

Blood pressure reduction is the most significant factor in delaying onset and progression of renal disease. Blockade of the renin-angiotensin system (RAS) using angiotensin-converting enzyme inhibitors (ACEIs) delays renal disease progression. More recently, agents that block the RAS by preventing angiotensin II from binding to its subtype 1 receptor (ARBs) have been developed in an effort to prevent deleterious consequences of pathologic levels of angiotensin II and to reduce the adverse effects of RAS blockade associated with ACEIs. Human studies with a variety of ARBs have clearly demonstrated the antihypertensive and antiproteinuric efficacy of these agents in patients with progressive renal diseases. Moreover, the effects of ARBs are similar or identical to those of ACEIs. Ongoing long-term clinical trials are designed to determine whether ARBs also preserve renal function similar to ACEIs. Specifically, the role of ARBs in patients with hypertension and type 2 diabetes is being evaluated in 3 large trials, including Appropriate Blood Pressure Control in Diabetes—Part 2 With Valsartan, the Losartan Renal Protection Study, and the Irbesartan Diabetic Nephropathy Trial. Definitive evidence of the long-term protective effects of ARBs in chronic progressive renal disease is expected from these important studies.

From the Department of Medicine, University of Texas Southwestern Medical Center, Dallas.

RELATED ARTICLE

Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 2001;161(12):1560-1561.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Preoperative Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Is Associated with Increased Risk for Acute Kidney Injury after Cardiovascular Surgery
Arora et al.
CJASN 2008;3:1266-1273.
ABSTRACT | FULL TEXT  

Preventing Renal Complications in Type 2 Diabetes: Results of the Diabetics Exposed to Telmisartan and Enalapril Trial
Barnett
J. Am. Soc. Nephrol. 2006;17:S132-S135.
ABSTRACT | FULL TEXT  

Review: Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold?
Weber
Journal of Renin-Angiotensin-Aldosterone System 2003;4:62-73.
ABSTRACT  

Angiotensin II Receptor-Independent Antiinflammatory and Antiaggregatory Properties of Losartan: Role of the Active Metabolite EXP3179
Kramer et al.
Circ. Res. 2002;90:770-776.
ABSTRACT | FULL TEXT  

Angiotensin II Receptor-Independent Antiinflammatory and Antiaggregatory Properties of Losartan: Role of the Active Metabolite EXP3179
Kramer et al.
Circ. Res. 2002;90:770-776.
ABSTRACT | FULL TEXT